A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel

Inclusion Criteria:

* Histologically documented adenocarcinoma of the prostate
* Previous treatment with either radical prostatectomy or radiation therapy
* Salvage radiotherapy for local relapse allowed
* Neoadjuvant or per radiotherapy Hormonal therapy allowed in case of more than 6 months free-interval before first rising PSA
* Life expectancy of more than 12 months
* Non metastatic disease documented by imaging including radionuclide bone scan
* ECOG performance status 0-1
* ANC \> 1,500/mm3
* Platelet counts \> 100,000/mm3
* SGOT and/or SGPT may be up to 2.5 x ULN

Patients at high risk of biological relapse defined by:

* Gleason \> 8
* PSA-DT \< 6 months
* Positive surgical margins
* PSA velocity \> 0.75 ng/mL/year
* Pathological pelvic lymph nodes involvement (pN+)
* Time from initial treatment until inclusion \< 12 months

Exclusion Criteria:

* Prior chemotherapy by taxanes and estramustine phosphate
* Documented local recurrence of prostate cancer or documented metastatic disease
* History of other malignancy within the last 5 years other than curatively treated basal cell carcinoma of the skin
* Active infection
* Significant cardiac disease, angina pectoris or myocardial infarction within twelve months
* Clinically significant neuropathy
* Medical condition requiring the use of concomitant corticosteroids
* Prohibited concomitant therapy with experimental drug.
* Participation in another clinical trial for the period \< 30 days